MK0916

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for MK0916, covering 2014-02-14 to 2015-05-22. Get the full timeline:

Most recent: Clinical Trial Update: MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005) [Phase 2]